Recurrent ulcer after successful treatment with cimetidine or antacid
This study was designed to compare the rates of duodenal ulcer healing and recurrence after treatment with cimetidine or antacid. Patients with endoscopically documented duodenal ulcer received cimetidine, 1200 mg daily, or Mylanta II, 7 oz daily, in a randomized, double-blind trial. For the 69 pati...
Gespeichert in:
| Veröffentlicht in: | Gastroenterology (New York, N.Y. 1943) N.Y. 1943), 1983-10, Vol.85 (4), p.875-880 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 880 |
|---|---|
| container_issue | 4 |
| container_start_page | 875 |
| container_title | Gastroenterology (New York, N.Y. 1943) |
| container_volume | 85 |
| creator | Ippoliti, A. Elashoff, J. Valenzuela, J. Cano, R. Frankl, H. Samloff, M. Koretz, R. |
| description | This study was designed to compare the rates of duodenal ulcer healing and recurrence after treatment with cimetidine or antacid. Patients with endoscopically documented duodenal ulcer received cimetidine, 1200 mg daily, or Mylanta II, 7 oz daily, in a randomized, double-blind trial. For the 69 patients in each group who completed the healing phase of the trial, endoscopic ulcer healing was almost identical. At 2, 4, and 6 wk, the cumulative percent healed on antacid was 33%, 64%, and 80%, and on cimetidine it was 25%, 62%, and 86%. The 114 patients with healed ulcer were observed on no therapy and underwent additional endoscopy to detect recurrences when symptomatic or at 3, 6, and 12 mo. There was no difference in the frequency of recurrences between treatments. At 3 and 6 mo, the cumulative percentages of patients with recurrence were 29% and 56% after antacid therapy and 36% and 55% after cimetidine therapy. Some patient variables were associated with delayed ulcer healing or ulcer recurrence. These included sex, pain frequency, smoking, disease duration, and acid secretion. |
| doi_str_mv | 10.1016/0016-5085(83)90439-0 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_80613727</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>0016508583904390</els_id><sourcerecordid>80613727</sourcerecordid><originalsourceid>FETCH-LOGICAL-c432t-854904b8395bb8a9d1350fc5697906aedd274d11a9a6cbf47d9208d059c3bbef3</originalsourceid><addsrcrecordid>eNp9kMtKAzEUhoMotVbfQGEWIroYTSZzSTaClHqBgiC6DpmTMxiZS00yim9vakuXbk4C_3cOPx8hp4xeM8rKGxpHWlBRXAp-JWnOZUr3yJQVmUhjlu2T6Q45JEfef1BKJRdsQiYlL-K_mpLFC8LoHPYhGVtAl-gmxOlHAPS-GdskONShWwPfNrwnYDsM1tgekyHSfdBgzTE5aHTr8WT7zsjb_eJ1_pgunx-e5nfLFHKehVQUeexZCy6LuhZaGhZrNFCUspK01GhMVuWGMS11CXWTV0ZmVBhaSOB1jQ2fkYvN3ZUbPkf0QXXWA7at7nEYvRK0ZLzKqgjmGxDc4L3DRq2c7bT7UYyqtT21VqPWapTg6s-eonHtbHt_rDs0u6Wtrpifb3PtQbeN0z1Yv8NkXnEhRMRuNxhGF18WnfJgsQc01iEEZQb7f49foCyLFQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>80613727</pqid></control><display><type>article</type><title>Recurrent ulcer after successful treatment with cimetidine or antacid</title><source>MEDLINE</source><source>ScienceDirect Journals (5 years ago - present)</source><source>Alma/SFX Local Collection</source><creator>Ippoliti, A. ; Elashoff, J. ; Valenzuela, J. ; Cano, R. ; Frankl, H. ; Samloff, M. ; Koretz, R.</creator><creatorcontrib>Ippoliti, A. ; Elashoff, J. ; Valenzuela, J. ; Cano, R. ; Frankl, H. ; Samloff, M. ; Koretz, R.</creatorcontrib><description>This study was designed to compare the rates of duodenal ulcer healing and recurrence after treatment with cimetidine or antacid. Patients with endoscopically documented duodenal ulcer received cimetidine, 1200 mg daily, or Mylanta II, 7 oz daily, in a randomized, double-blind trial. For the 69 patients in each group who completed the healing phase of the trial, endoscopic ulcer healing was almost identical. At 2, 4, and 6 wk, the cumulative percent healed on antacid was 33%, 64%, and 80%, and on cimetidine it was 25%, 62%, and 86%. The 114 patients with healed ulcer were observed on no therapy and underwent additional endoscopy to detect recurrences when symptomatic or at 3, 6, and 12 mo. There was no difference in the frequency of recurrences between treatments. At 3 and 6 mo, the cumulative percentages of patients with recurrence were 29% and 56% after antacid therapy and 36% and 55% after cimetidine therapy. Some patient variables were associated with delayed ulcer healing or ulcer recurrence. These included sex, pain frequency, smoking, disease duration, and acid secretion.</description><identifier>ISSN: 0016-5085</identifier><identifier>EISSN: 1528-0012</identifier><identifier>DOI: 10.1016/0016-5085(83)90439-0</identifier><identifier>PMID: 6350097</identifier><identifier>CODEN: GASTAB</identifier><language>eng</language><publisher>New York, NY: Elsevier Inc</publisher><subject>Aluminum Hydroxide - therapeutic use ; Antacids - therapeutic use ; Biological and medical sciences ; Cimetidine - therapeutic use ; Clinical Trials as Topic ; Digestive system ; Double-Blind Method ; Drug Combinations - therapeutic use ; Duodenal Ulcer - diagnosis ; Duodenal Ulcer - drug therapy ; Female ; Guanidines - therapeutic use ; Humans ; Magnesium - therapeutic use ; Magnesium Hydroxide - therapeutic use ; Male ; Medical sciences ; Middle Aged ; Pharmacology. Drug treatments ; Recurrence ; Silicones - therapeutic use ; Simethicone - therapeutic use</subject><ispartof>Gastroenterology (New York, N.Y. 1943), 1983-10, Vol.85 (4), p.875-880</ispartof><rights>1983</rights><rights>1984 INIST-CNRS</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c432t-854904b8395bb8a9d1350fc5697906aedd274d11a9a6cbf47d9208d059c3bbef3</citedby><cites>FETCH-LOGICAL-c432t-854904b8395bb8a9d1350fc5697906aedd274d11a9a6cbf47d9208d059c3bbef3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/0016-5085(83)90439-0$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,780,784,3550,27924,27925,45995</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=9473888$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/6350097$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Ippoliti, A.</creatorcontrib><creatorcontrib>Elashoff, J.</creatorcontrib><creatorcontrib>Valenzuela, J.</creatorcontrib><creatorcontrib>Cano, R.</creatorcontrib><creatorcontrib>Frankl, H.</creatorcontrib><creatorcontrib>Samloff, M.</creatorcontrib><creatorcontrib>Koretz, R.</creatorcontrib><title>Recurrent ulcer after successful treatment with cimetidine or antacid</title><title>Gastroenterology (New York, N.Y. 1943)</title><addtitle>Gastroenterology</addtitle><description>This study was designed to compare the rates of duodenal ulcer healing and recurrence after treatment with cimetidine or antacid. Patients with endoscopically documented duodenal ulcer received cimetidine, 1200 mg daily, or Mylanta II, 7 oz daily, in a randomized, double-blind trial. For the 69 patients in each group who completed the healing phase of the trial, endoscopic ulcer healing was almost identical. At 2, 4, and 6 wk, the cumulative percent healed on antacid was 33%, 64%, and 80%, and on cimetidine it was 25%, 62%, and 86%. The 114 patients with healed ulcer were observed on no therapy and underwent additional endoscopy to detect recurrences when symptomatic or at 3, 6, and 12 mo. There was no difference in the frequency of recurrences between treatments. At 3 and 6 mo, the cumulative percentages of patients with recurrence were 29% and 56% after antacid therapy and 36% and 55% after cimetidine therapy. Some patient variables were associated with delayed ulcer healing or ulcer recurrence. These included sex, pain frequency, smoking, disease duration, and acid secretion.</description><subject>Aluminum Hydroxide - therapeutic use</subject><subject>Antacids - therapeutic use</subject><subject>Biological and medical sciences</subject><subject>Cimetidine - therapeutic use</subject><subject>Clinical Trials as Topic</subject><subject>Digestive system</subject><subject>Double-Blind Method</subject><subject>Drug Combinations - therapeutic use</subject><subject>Duodenal Ulcer - diagnosis</subject><subject>Duodenal Ulcer - drug therapy</subject><subject>Female</subject><subject>Guanidines - therapeutic use</subject><subject>Humans</subject><subject>Magnesium - therapeutic use</subject><subject>Magnesium Hydroxide - therapeutic use</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Pharmacology. Drug treatments</subject><subject>Recurrence</subject><subject>Silicones - therapeutic use</subject><subject>Simethicone - therapeutic use</subject><issn>0016-5085</issn><issn>1528-0012</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1983</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kMtKAzEUhoMotVbfQGEWIroYTSZzSTaClHqBgiC6DpmTMxiZS00yim9vakuXbk4C_3cOPx8hp4xeM8rKGxpHWlBRXAp-JWnOZUr3yJQVmUhjlu2T6Q45JEfef1BKJRdsQiYlL-K_mpLFC8LoHPYhGVtAl-gmxOlHAPS-GdskONShWwPfNrwnYDsM1tgekyHSfdBgzTE5aHTr8WT7zsjb_eJ1_pgunx-e5nfLFHKehVQUeexZCy6LuhZaGhZrNFCUspK01GhMVuWGMS11CXWTV0ZmVBhaSOB1jQ2fkYvN3ZUbPkf0QXXWA7at7nEYvRK0ZLzKqgjmGxDc4L3DRq2c7bT7UYyqtT21VqPWapTg6s-eonHtbHt_rDs0u6Wtrpifb3PtQbeN0z1Yv8NkXnEhRMRuNxhGF18WnfJgsQc01iEEZQb7f49foCyLFQ</recordid><startdate>198310</startdate><enddate>198310</enddate><creator>Ippoliti, A.</creator><creator>Elashoff, J.</creator><creator>Valenzuela, J.</creator><creator>Cano, R.</creator><creator>Frankl, H.</creator><creator>Samloff, M.</creator><creator>Koretz, R.</creator><general>Elsevier Inc</general><general>Elsevier</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>198310</creationdate><title>Recurrent ulcer after successful treatment with cimetidine or antacid</title><author>Ippoliti, A. ; Elashoff, J. ; Valenzuela, J. ; Cano, R. ; Frankl, H. ; Samloff, M. ; Koretz, R.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c432t-854904b8395bb8a9d1350fc5697906aedd274d11a9a6cbf47d9208d059c3bbef3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1983</creationdate><topic>Aluminum Hydroxide - therapeutic use</topic><topic>Antacids - therapeutic use</topic><topic>Biological and medical sciences</topic><topic>Cimetidine - therapeutic use</topic><topic>Clinical Trials as Topic</topic><topic>Digestive system</topic><topic>Double-Blind Method</topic><topic>Drug Combinations - therapeutic use</topic><topic>Duodenal Ulcer - diagnosis</topic><topic>Duodenal Ulcer - drug therapy</topic><topic>Female</topic><topic>Guanidines - therapeutic use</topic><topic>Humans</topic><topic>Magnesium - therapeutic use</topic><topic>Magnesium Hydroxide - therapeutic use</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Pharmacology. Drug treatments</topic><topic>Recurrence</topic><topic>Silicones - therapeutic use</topic><topic>Simethicone - therapeutic use</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Ippoliti, A.</creatorcontrib><creatorcontrib>Elashoff, J.</creatorcontrib><creatorcontrib>Valenzuela, J.</creatorcontrib><creatorcontrib>Cano, R.</creatorcontrib><creatorcontrib>Frankl, H.</creatorcontrib><creatorcontrib>Samloff, M.</creatorcontrib><creatorcontrib>Koretz, R.</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Gastroenterology (New York, N.Y. 1943)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Ippoliti, A.</au><au>Elashoff, J.</au><au>Valenzuela, J.</au><au>Cano, R.</au><au>Frankl, H.</au><au>Samloff, M.</au><au>Koretz, R.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Recurrent ulcer after successful treatment with cimetidine or antacid</atitle><jtitle>Gastroenterology (New York, N.Y. 1943)</jtitle><addtitle>Gastroenterology</addtitle><date>1983-10</date><risdate>1983</risdate><volume>85</volume><issue>4</issue><spage>875</spage><epage>880</epage><pages>875-880</pages><issn>0016-5085</issn><eissn>1528-0012</eissn><coden>GASTAB</coden><abstract>This study was designed to compare the rates of duodenal ulcer healing and recurrence after treatment with cimetidine or antacid. Patients with endoscopically documented duodenal ulcer received cimetidine, 1200 mg daily, or Mylanta II, 7 oz daily, in a randomized, double-blind trial. For the 69 patients in each group who completed the healing phase of the trial, endoscopic ulcer healing was almost identical. At 2, 4, and 6 wk, the cumulative percent healed on antacid was 33%, 64%, and 80%, and on cimetidine it was 25%, 62%, and 86%. The 114 patients with healed ulcer were observed on no therapy and underwent additional endoscopy to detect recurrences when symptomatic or at 3, 6, and 12 mo. There was no difference in the frequency of recurrences between treatments. At 3 and 6 mo, the cumulative percentages of patients with recurrence were 29% and 56% after antacid therapy and 36% and 55% after cimetidine therapy. Some patient variables were associated with delayed ulcer healing or ulcer recurrence. These included sex, pain frequency, smoking, disease duration, and acid secretion.</abstract><cop>New York, NY</cop><pub>Elsevier Inc</pub><pmid>6350097</pmid><doi>10.1016/0016-5085(83)90439-0</doi><tpages>6</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0016-5085 |
| ispartof | Gastroenterology (New York, N.Y. 1943), 1983-10, Vol.85 (4), p.875-880 |
| issn | 0016-5085 1528-0012 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_80613727 |
| source | MEDLINE; ScienceDirect Journals (5 years ago - present); Alma/SFX Local Collection |
| subjects | Aluminum Hydroxide - therapeutic use Antacids - therapeutic use Biological and medical sciences Cimetidine - therapeutic use Clinical Trials as Topic Digestive system Double-Blind Method Drug Combinations - therapeutic use Duodenal Ulcer - diagnosis Duodenal Ulcer - drug therapy Female Guanidines - therapeutic use Humans Magnesium - therapeutic use Magnesium Hydroxide - therapeutic use Male Medical sciences Middle Aged Pharmacology. Drug treatments Recurrence Silicones - therapeutic use Simethicone - therapeutic use |
| title | Recurrent ulcer after successful treatment with cimetidine or antacid |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-06T19%3A04%3A38IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Recurrent%20ulcer%20after%20successful%20treatment%20with%20cimetidine%20or%20antacid&rft.jtitle=Gastroenterology%20(New%20York,%20N.Y.%201943)&rft.au=Ippoliti,%20A.&rft.date=1983-10&rft.volume=85&rft.issue=4&rft.spage=875&rft.epage=880&rft.pages=875-880&rft.issn=0016-5085&rft.eissn=1528-0012&rft.coden=GASTAB&rft_id=info:doi/10.1016/0016-5085(83)90439-0&rft_dat=%3Cproquest_cross%3E80613727%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=80613727&rft_id=info:pmid/6350097&rft_els_id=0016508583904390&rfr_iscdi=true |